325 related articles for article (PubMed ID: 27802969)
1. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
2. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Georgantopoulos P; Yang H; Norris LB; Bennett CL
Cancer Med; 2019 May; 8(5):2233-2240. PubMed ID: 30983123
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
Emond B; Sundaram M; Romdhani H; Lefebvre P; Wang S; Mato A
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):763-775.e2. PubMed ID: 31678080
[TBL] [Abstract][Full Text] [Related]
4. Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Shadman M; Tedeschi A; Mohseninejad L; Yang K; Lamanna N; Xu S; Cohen A; Challagulla S; Xue M; Williams R; O'Brien SM; Brown JR; Tam C
Blood Cancer J; 2024 May; 14(1):77. PubMed ID: 38697986
[No Abstract] [Full Text] [Related]
5. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
Tucker DL; Rule SA
Ther Clin Risk Manag; 2015; 11():979-90. PubMed ID: 26150724
[TBL] [Abstract][Full Text] [Related]
6. Tongue graft-versus-host disease: remission with ruxolitinib.
Grafanaki K; Lygeros S; Spyridonidis A; Liga M
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35606043
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis: a new adverse event of ibrutinib.
Rapparini L; Massi A; Baraldi C; Gugliotta G; Pileri A
Ital J Dermatol Venerol; 2024 Apr; 159(2):205-207. PubMed ID: 38287741
[No Abstract] [Full Text] [Related]
8. Ibrutinib in the real world patient: many lights and some shades.
Ghia P; Cuneo A
Haematologica; 2016 Dec; 101(12):1448-1450. PubMed ID: 27903711
[No Abstract] [Full Text] [Related]
9. Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
Mauro FR; Giannarelli D; Visentin A; Reda G; Sportoletti P; Frustaci AM; Chiarenza A; Ciolli S; Vitale C; Laurenti L; De Paoli L; Murru R; Gentile M; Rigolin GM; Levato L; Giordano A; Del Poeta G; Stelitano C; Ielo C; Noto A; Guarente V; Molica S; Coscia M; Tedeschi A; Gaidano G; Cuneo A; Foà R; Martelli M; Girmenia C; Gentile G; Trentin L
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209515
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib reversal of immune exhaustion in CLL.
Moss P
Blood; 2024 Jan; 143(1):5-7. PubMed ID: 38175677
[No Abstract] [Full Text] [Related]
11. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
[TBL] [Abstract][Full Text] [Related]
12. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Barr PM; Brown JR; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Mulligan SP; Jaeger U; Furman RR; Cymbalista F; Montillo M; Dearden C; Robak T; Moreno C; Pagel JM; Burger JA; Suzuki S; Sukbuntherng J; Cole G; James DF; Byrd JC
Blood; 2017 May; 129(19):2612-2615. PubMed ID: 28373262
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
14. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
15. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
16. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
[No Abstract] [Full Text] [Related]
17. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
18. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
